Tarsus Pharmaceuticals Inc (NAS:TARS)
$ 55 0.65 (1.2%) Market Cap: 2.10 Bil Enterprise Value: 1.83 Bil PE Ratio: 0 PB Ratio: 8.85 GF Score: 48/100

Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 05:30PM GMT
Release Date Price: $26.11 (-5.84%)
Matthew Kaplan
Ladenburg Thalmann & Co. Inc. - Analyst

It's my pleasure to introduce our next presenting company, Tarsus. Presenting for the Company today will be the CEO, Bobby Azamian. Bobby, thank you for taking part in our conference today. And I'm going to hand the podium over to you and give you a chance to present the Company, and then hopefully, we will have time for questions after your introduction.

Bobby Azamian
Tarsus Pharmaceuticals, Inc. - President and CEO

Thank you, Matt. Really a pleasure to be with you here today. And I'm excited to introduce the audience -- or update the audience, depending on the investors listening to Tarsus, in what we're up to. So I will be making forward-looking statements.

And I wanted to start with our vision and mission. So from day 1, we've been focused on really charting new ground and developing a brand-new drug for a brand-new indication. That's TP-03 for Demodex blepharitis. And I started the Company with that mission, to not only deliver a really important new therapy but also a scalable company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot